此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

人溶菌酶山羊奶用于预防接受供体干细胞移植的血癌患者的移植物抗宿主病

2026年11月9日 更新者:City of Hope Medical Center

人溶菌酶山羊奶在标准清髓性同种异体造血干细胞移植受者中的随机试验研究

This phase I trial studies the side effects of human lysozyme goat milk in preventing graft versus host disease in patients with blood cancer undergoing a donor stem cell transplant. Sometimes the transplanted cells from a donor can cause an immune response against the body's own normal cells (call graft versus host disease). The goat milk in the study is from goats that have been genetically engineered to produce human lysozyme in the milk. Human lysozyme is a natural enzyme found in human milk and acts as an antimicrobial. Lysozyme is key to the digestive health of breast-fed human infants, since it helps the growth of beneficial gut bacteria and reduces the growth of bacteria that causes diarrhea and intestinal disease. Giving human lysozyme goat milk may reduce the rate of graft versus host disease in blood cancer patients undergoing a donor stem cell transplant.

研究概览

详细说明

PRIMARY OBJECTIVES:

I. To evaluate the safety and feasibility of human lysozyme goat milk (hLZ) treatment by assessing:

Ia: Type, frequency, severity, attribution, time course and duration of adverse events, including diarrhea, bloodstream/intestinal infections.

Ib. Patients' ability to drink the specified volume (250 ml 3 x/day) of hLZ during the treatment period.

SECONDARY OBJECTIVES:

I. To compare the incidence and severity of adverse events (AE) among hLZ-treated and untreated patients, including diarrhea, bloodstream infections and intestinal infections.

II. To obtain preliminary estimates of gut microbiome diversity, as assessed by the Simpson Index, in hLZ-treated/untreated patients.

III. To compare gut microbiome diversity among hLZ-treated/untreated patients. IV. To obtain a preliminary estimate of the possible association between gut microbiome diversity and bloodstream infections.

V. To obtain a preliminary estimate of the possible association between gut microbiome diversity and acute graft versus host disease (GVHD) cumulative incidence, including time to onset.

VI. To characterize and compare GVHD inflammatory biomarkers (presence, level) among hLZ-treated and untreated patients.

VII. To characterize and compare urinary uindoxyl sulfate, tryptophan and kynurenine levels between hLZ-treated and untreated patients.

IX. To obtain a preliminary estimate of gut microbiome diversity and calorie intake.

X. To estimate overall survival (OS) cumulative incidence (CI) chronic GVHD of relapse/progression, and non-relapse mortality (NRM) at 100 days (excluding chronic GVHD), 6 months, 1 year and 2 years.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP A:

CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo fractionated total body irradiation (FTBI) on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per City of Hope (COH) standard operating procedure (SOP) in the absence of disease progression or unacceptable toxicity.

HLZ: Patients receive human lysozyme goat milk orally (PO) three times daily (TID) on days -8 to 28 in the absence of disease progression or unacceptable toxicity.

TRANSPLANT: Patients undergo stem cell transplant on day 0.

GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity.

GROUP B:

CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.

TRANSPLANT: Patients undergo stem cell transplant on day 0.

GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity.

After the completion of study treatment, patients are followed up for up to 30-100 days and then up to 2 years after transplant.

研究类型

介入性

注册 (实际的)

52

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Duarte、California、美国、91010
        • City of Hope Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

12年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Documented informed consent of the participant and/or legally authorized representative

  • Willingness to be followed for the planned duration of the trial (2 years)

  • All subjects must have the ability to understand and the willingness to sign a written informed consent

  • Karnofsky performance status >= 60 per COH SOP

  • Patients must be undergoing allogeneic hematopoietic stem cell transplantation (alloHCT) for hematologic malignancies from matched related or matched unrelated donors with 8/8 (A, B, C, DRB 1) high resolution human leukocyte antigen (HLA) donor allele matching

  • Patients must be receiving a fractionated total body radiation (FTBI) based- myeloablative conditioning regimen; (acceptable conditioning regimens include total body irradiation [TBI] + cyclophosphamide or TBI + etoposide)

  • Ejection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) > 50%

  • Diffusing capacity for carbon monoxide (DLCO) adjusted for hemoglobin or forced vital capacity (FVC) > 50% predicted

  • Total serum bilirubin < 2 times upper limit of normal

  • Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x the upper normal limit

  • Alkaline phosphatase =< 2.5 x the upper normal limit

  • Measured creatinine clearance more than 60 mL/min

  • Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through 90 days after the last dose of protocol therapy

    • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

Exclusion Criteria:

  • Failure of research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this pilot study. A legal guardian may substitute for the research participant
  • Research participants receiving any other investigational agents
  • Research participants with presence of other active malignancy within 2 years of study entry. Participants with history of prior malignancy treated with curative intent who achieved complete remission (CR) more than 2 years before study entry are eligible. This exclusion rule does not apply to non-melanoma skin tumors and in-situ cervical cancer
  • Research participants having any uncontrolled illness including ongoing or active infection. Research participants with known active hepatitis B or C infection; research participants who are human immunodeficiency virus (HIV) seropositive based on testing performed within 4 weeks of enrollment; research participants with any signs or symptoms of active infection, positive blood cultures, or radiological evidence of infections
  • Refusing to use contraception up to 90 days post-HCT
  • Pregnant and/or breast feeding if a female recipient
  • Lactose intolerance or intolerance to milk products
  • In the opinion of the principal investigator (PI), the participant has a condition that will preclude them from complying with study treatment

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Group A (conditioning, goat milk, transplant, prophylaxis)

CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.

HLZ: Patients receive human lysozyme goat milk PO TID on days -8 to 28 in the absence of disease progression or unacceptable toxicity.

TRANSPLANT: Patients undergo stem cell transplant on day 0.

GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity.

Given IV

其他名称:
  • 胞毒素
  • CTX
  • (-)-环磷酰胺
  • 2H-1,3,2-氧氮杂膦,2-[双(2-氯乙基)氨基]四氢-,2-氧化物,一水合物
  • 卡洛生
  • 环磷酰胺
  • 环草醛
  • 克拉芬
  • CP一水合物
  • 循环电池
  • 环胚素
  • 环爆碱
  • 环磷酰胺一水合物
  • 环磷烷
  • 环磷脂
  • 环素
  • 环孢菌素
  • 胞磷
  • 胞磷烷
  • 磷脂龙
  • Genoxal
  • Genuxal
  • 雷多西那
  • 米托生
  • 新星
  • 重免疫
  • 赛克磷酰胺
  • WR- 138719

Given IV

其他名称:
  • 去甲基鬼臼毒素乙苷
  • EPEG
  • 拉斯特
  • 拓扑萨
  • 韦贝斯
  • 副总裁 16
  • 副总裁 16-213
  • VP-16
  • VP-16-213
  • VP16

Given PO

其他名称:
  • 拉帕蒙
  • AY 22989
  • 拉帕
  • 雷帕霉素
  • 西拉9268A
  • WY-090217

Undergo allo-HCT

其他名称:
  • 同种异体造血细胞移植
  • 高等学校
  • HSCT
  • 同种异体干细胞移植

Undergo FTBI

其他名称:
  • 分割立体定向放射治疗

Given human lysozyme goat milk PO

Given IV

其他名称:
  • 生长因子,重组人角质形成细胞
  • 凯普万斯
  • 角质形成细胞生长因子,重组人
  • 重组人角化细胞生长因子
  • rhKGF
  • rhu 角质形成细胞生长因子

Given IV and PO

其他名称:
  • 程序
  • 希科里亚
  • FK 506
  • 富士霉素
  • 原主题
有源比较器:Group B (conditioning, transplant, prophylaxis)

CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.

TRANSPLANT: Patients undergo stem cell transplant on day 0.

GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity.

Given IV

其他名称:
  • 胞毒素
  • CTX
  • (-)-环磷酰胺
  • 2H-1,3,2-氧氮杂膦,2-[双(2-氯乙基)氨基]四氢-,2-氧化物,一水合物
  • 卡洛生
  • 环磷酰胺
  • 环草醛
  • 克拉芬
  • CP一水合物
  • 循环电池
  • 环胚素
  • 环爆碱
  • 环磷酰胺一水合物
  • 环磷烷
  • 环磷脂
  • 环素
  • 环孢菌素
  • 胞磷
  • 胞磷烷
  • 磷脂龙
  • Genoxal
  • Genuxal
  • 雷多西那
  • 米托生
  • 新星
  • 重免疫
  • 赛克磷酰胺
  • WR- 138719

Given IV

其他名称:
  • 去甲基鬼臼毒素乙苷
  • EPEG
  • 拉斯特
  • 拓扑萨
  • 韦贝斯
  • 副总裁 16
  • 副总裁 16-213
  • VP-16
  • VP-16-213
  • VP16

Given PO

其他名称:
  • 拉帕蒙
  • AY 22989
  • 拉帕
  • 雷帕霉素
  • 西拉9268A
  • WY-090217

Undergo allo-HCT

其他名称:
  • 同种异体造血细胞移植
  • 高等学校
  • HSCT
  • 同种异体干细胞移植

Undergo FTBI

其他名称:
  • 分割立体定向放射治疗

Given IV

其他名称:
  • 生长因子,重组人角质形成细胞
  • 凯普万斯
  • 角质形成细胞生长因子,重组人
  • 重组人角化细胞生长因子
  • rhKGF
  • rhu 角质形成细胞生长因子

Given IV and PO

其他名称:
  • 程序
  • 希科里亚
  • FK 506
  • 富士霉素
  • 原主题

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Patients' ability to drink the specified daily amount of 750 ml human lysozyme goat milk (hLZ)
大体时间:from study initiation until up to 28 days post-transplant or until discharge, whoever comes first

In the safety lead-in phase, we are going to investigate if a patient can drink the daily amount of 750 ml of hLZ.. The actual volume of milk consumed per day will be measured using graduated cups and recorded on daily basis.

To calculate the average daily consumption, total volume of hLZ consumed by each patient for the whole inpatient stay will be divided by the total number of inpatient stay for that patient. Tolerable dose established based on the average daily hLZ consumption in the first 6 patients (safety lead-in) will be brought forward for additional study randomization.

from study initiation until up to 28 days post-transplant or until discharge, whoever comes first
Unacceptable toxicity
大体时间:Up to 28 days post-transplant or date of discharge

The modified Bearman Scale will be used to define unacceptable toxicity events. Unacceptable toxicity in a given patient is defined as either of the following that are considered at least possibly related to drinking hLZ milk: GI toxicity grade III or IV per Bearman scale or inability to consume hLZ milk for > 7 days.

Up to 28 days post-transplant or date of discharge
Adverse events
大体时间:Up to 100 days post-transplant

Incidence and severity of adverse events will be reported according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.03. Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study treatment and reversibility or outcome.

Up to 100 days post-transplant
Volume of hLZ consumed
大体时间:Up to 28 days post-transplant or date of discharge

Tolerability is defined as the ability to consume >= 150 ml/day over the treatment period.

Up to 28 days post-transplant or date of discharge

次要结果测量

结果测量
措施说明
大体时间
Cumulative incidence (CI) of chronic graft versus host disease (GVHD)
大体时间:At 6 months

Chronic graft versus host disease is scored according to NIH Consensus Staging. The first day of chronic GvHD onset will be used to calculate confidence interval (CI) incidence curves, with relapse/death prior to onset considered competing events. CI of chronic GVHD will be estimated using the method described by Gooley et al (1999).

At 6 months
Cumulative incidence (CI) of chronic GVHD
大体时间:At 1 year

Chronic graft versus host disease is scored according to NIH Consensus Staging. The first day of chronic GvHD onset will be used to calculate CI incidence curves, with relapse/death prior to onset considered competing events. CI of chronic GVHD will be estimated using the method described by Gooley et al (1999).

At 1 year
Cumulative incidence (CI) of chronic GVHD
大体时间:At 2 years

Chronic graft versus host disease is scored according to NIH Consensus Staging. The first day of chronic GvHD onset will be used to calculate CI incidence curves, with relapse/death prior to onset considered competing events. CI of chronic GVHD will be estimated using the method described by Gooley et al (1999).

At 2 years
CI of non-relapse mortality (NRM)
大体时间:At 100 days

Non-relapse mortality (NRM) is defined as death occurring in a patient from causes other than relapse. NRM is measured from start of treatment until non-disease related death, or last follow-up, whichever comes first. The cumulative incidence of NRM will be calculated reflecting relapse as a competing risk. CI of NRM will be estimated using the method described by Gooley et al (1999).

At 100 days
CI of NRM
大体时间:At 1 year

Non-relapse mortality (NRM) is defined as death occurring in a patient from causes other than relapse. NRM is measured from start of treatment until non-disease related death, or last follow-up, whichever comes first. The cumulative incidence of NRM will be calculated reflecting relapse as a competing risk. CI of NRM will be estimated using the method described by Gooley et al (1999).

At 1 year
CI of NRM
大体时间:At 2 years

Non-relapse mortality (NRM) is defined as death occurring in a patient from causes other than relapse. NRM is measured from start of treatment until non-disease related death, or last follow-up, whichever comes first. The cumulative incidence of NRM will be calculated reflecting relapse as a competing risk. CI of NRM will be estimated using the method described by Gooley et al (1999).

At 2 years
CI of relapse/progression
大体时间:At 100 days

The event is relapse/progression. Time to this event is measured from start of treatment. Death without relapse/progression is considered a competing risk. Surviving patients with no history of relapse are censored at time of last follow-up. CI of relapse/progression will be estimated using the method described by Gooley et al (1999).

At 100 days
CI of relapse/progression
大体时间:At 1 year

The event is relapse/progression. Time to this event is measured from start of treatment. Death without relapse/progression is considered a competing risk. Surviving patients with no history of relapse are censored at time of last follow-up. CI of relapse/progression will be estimated using the method described by Gooley et al (1999).

At 1 year
CI of relapse/progression
大体时间:At 2 years

The event is relapse/progression. Time to this event is measured from start of treatment. Death without relapse/progression is considered a competing risk. Surviving patients with no history of relapse are censored at time of last follow-up. CI of relapse/progression will be estimated using the method described by Gooley et al (1999).

At 2 years
Gut microbiome diversity
大体时间:Day - 8 +/- 3, day 0, day +7, day +14, day +21, day +28

Gut microbiome diversity will be assessed by the Simpson Index and compared between hLZ-treated/untreated patients. Association between treatment and gut microbial diversity will be assessed by Fisher's Exact test.

Day - 8 +/- 3, day 0, day +7, day +14, day +21, day +28
CI of acute graft versus host disease (aGVHD)
大体时间:At 100 days

Acute graft versus host disease will be graded according to the Consensus Grading. The first day of acute GvHD onset at a certain grade will be used to calculate cumulative incidence curves for that GvHD grade; relapse/death prior to onset will be considered competing events. CI of aGVHD will be estimated using the method described by Gooley et al (1999). Association between gut microbial diversity (inverse Simpson index: high [> 4], intermediate [2-4], and low [< 2]) or treatment and CI of aGVHD will be assessed by Gray's test.

At 100 days
Incidence of bloodstream infections
大体时间:Up to 100 days

Incidence of bloodstream infections and infectious enterocolitis will be evaluated and a preliminary estimate of the association between gut microbiome diversity and bloodstream infections will be obtained. Association between gut microbial diversity (inverse Simpson index: high [> 4], intermediate [2-4], and low [< 2]) or treatment and CI of bloodstream infections will be assessed by Gray's test.

Up to 100 days
Overall survival (OS)
大体时间:At 100 days

Patients are considered a failure for this endpoint if they die, regardless of cause. The time to this event is the time from start of treatment until death, or last follow-up, whichever comes first. OS will be estimated using the product-limit method of Kaplan and Meier.

At 100 days
Overall survival (OS)
大体时间:At 1 year

Patients are considered a failure for this endpoint if they die, regardless of cause. The time to this event is the time from start of treatment until death, or last follow-up, whichever comes first. OS will be estimated using the product-limit method of Kaplan and Meier.

At 1 year
Overall survival (OS)
大体时间:At 2 years

Patients are considered a failure for this endpoint if they die, regardless of cause. The time to this event is the time from start of treatment until death, or last follow-up, whichever comes first. OS will be estimated using the product-limit method of Kaplan and Meier.

At 2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Karamjeet S Sandhu、City of Hope Medical Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年4月30日

初级完成 (实际的)

2025年12月29日

研究完成 (估计的)

2027年3月23日

研究注册日期

首次提交

2019年10月14日

首先提交符合 QC 标准的

2019年11月22日

首次发布 (实际的)

2019年11月26日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅